Gilead bags Sarep­ta's pri­or­i­ty re­view vouch­er for a dis­count, pay­ing $125M

Back in the sum­mer of 2015, Ab­b­Vie agreed to pay $350 mil­lion for a pri­or­i­ty re­view vouch­er, which can be used to shave four months off the sched­ule for any FDA drug re­view. But now, less than two years lat­er, the price has come down con­sid­er­ably.

Ear­ly Mon­day Sarep­ta $SRPT said that it has auc­tioned off its PRV for $125 mil­lion, still a con­sid­er­able sum of cash. Sarep­ta CEO Ed Kaye start­ed the sale process right af­ter the ap­proval for Ex­ondys 51 land­ed, look­ing for some added cash as they launched their drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER